Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVS ‘Guaranteed Net Cost’ Program Is Alternative To High Price/High Rebate Model

Executive Summary

Program likely to generate fewer rebates so it remains to be seen whether payers will embrace the new model in a big way.

Advertisement

Related Content

Mehta Analysis: Time Has Come To Present Drugs As Consumer Products
Express Scripts New Flex Formulary Will Prefer Lower-Priced Brand Alternatives
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
CVS Offering Point-Of-Sale Rebates In Part D Next Year With SilverScript Plan
CVS Will Retain $300M In Drug Rebates In 2018, PBM Says
CVS Launching Program To Exclude New Drugs Deemed Not Cost Effective
HHS Advancing Attack On Rebates With Proposal To Revoke Safe Harbor
PBMs Offering Prescribers Real Time Visibility On Cost-Sharing, Cheaper Alternatives

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel